Andrew Joseph Muir, MD

Professor of Medicine
Chief, Division of Gastroenterology in the Department of Medicine
Member in the Duke Clinical Research Institute
Campus mail 03137B Hosp South, Durham, NC 27710
Phone (919) 684-2052
Email address
  • Hepatitis C 
  • Primary sclerosing cholangitis
  • Cirrhosis
  • Liver Transplantation
  • Clinical Trials
  • Healthcare disparities in liver disease 
  • Outcomes Research
In Their Words

Education and Training

  • Fellow in Gastroenterology, Medicine, Duke University, 1998 - 2000
  • Chief Medical Resident, Medicine, Duke University, 1997 - 1998
  • Fellow in Gastroenterology, Medicine, Duke University, 1996 - 1997
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.H.S., Duke University, 2001
  • M.D., Duke University, 1993


Ratziu, V, Sanyal, AJ, Loomba, R, Caldwell, SH, Ghalib, RH, Torres, DM, McCullough, AJ, Muir, AJ, Myers, RP, Schall, REA, Subramanian, M, McHutchison, JG, Bosch, J, Harrison, SA, and Abdelmalek, MF. "Characterization of insulin resistance in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH)." October 2015.


Manns, MP, Eksteen, B, Shiffman, ML, Levy, C, Kowdley, KV, Montano-Loza, AJ, Janssen, HL, Myers, RP, Ding, D, Subramanian, M, McHutchison, JG, Charlton, MR, Bowlus, CL, Muir, AJ, and Chapman, RW. "Association between elevated serum IgG4 (sIgG4) concentrations and the phenotype of patients with primary sclerosing cholangitis (PSC)." October 2015.


Bowlus, CL, Patel, K, Guha, IN, Chapman, RW, Chazouilleres, O, Chalasani, NP, Vierling, JM, Myers, RP, Ding, D, Schall, REA, Subramanian, M, McHutchison, JG, Muir, AJ, Goodman, ZD, and Levy, C. "Validation of serum fibrosis marker panels in patients with primary sclerosing cholangitis (PSC) in a randomized trial of simtuzumab." October 2015.


French, D, Goodman, ZD, Huntzicker, EG, Newstrom, D, Karnik, S, Smith, V, Schall, REA, Kanwar, B, Subramanian, M, McHutchison, JG, Muir, AJ, and Myers, RP. "Expression of matrix metalloproteinase 9 (MMP9) and the apoptosis signal-regulating kinase 1 (ASK1) pathway activation marker, phospho-P38 (p-P38), in primary sclerosing cholangitis (PSC)." October 2015.


Muir, AJ, Charlton, MR, Pang, PS, Stamm, LM, Brainard, DM, McHutchison, JG, Afdhal, NH, and Watkins, PB. "Detecting Drug-Induced Liver Injury in Patients with Decompensated Chronic Hepatitis C: A Review of the SOLAR-1 and SOLAR-2 Studies." October 2015.


Charlton, M, Everson, GT, Flamm, SL, Kumar, P, Landis, C, Brown, RS, Fried, MW, Terrault, NA, O'Leary, JG, Vargas, HE, Kuo, A, Schiff, E, Sulkowski, MS, Gilroy, R, Watt, KD, Brown, K, Kwo, P, Pungpapong, S, Korenblat, KM, Muir, AJ, Teperman, L, Fontana, RJ, Denning, J, Arterburn, S, Dvory-Sobol, H, Brandt-Sarif, T, Pang, PS, McHutchison, JG, Reddy, KR, Afdhal, N, and SOLAR-1 Investigators, . "Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease." Gastroenterology 149, no. 3 (September 2015): 649-659.

Full Text

Shuldiner, SR, Gong, L, Muir, AJ, Altman, RB, and Klein, TE. "PharmGKB summary: peginterferon-α pathway." Pharmacogenetics and Genomics 25, no. 9 (September 2015): 465-474.

Full Text

Giannini, EG, Afdhal, NH, Sigal, SH, Muir, AJ, Reddy, KR, Vijayaraghavan, S, Elkashab, M, Romero-Gómez, M, Dusheiko, GM, Iyengar, M, Vasey, SY, Campbell, FM, and Theodore, D. "Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy." Journal of Gastroenterology and Hepatology 30, no. 8 (August 2015): 1301-1308.

Full Text

Ahmad, T, Yin, P, Saffitz, J, Pockros, PJ, Lalezari, J, Shiffman, M, Freilich, B, Zamparo, J, Brown, K, Dimitrova, D, Kumar, M, Manion, D, Heath-Chiozzi, M, Wolf, R, Hughes, E, Muir, AJ, and Hernandez, AF. "Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C." Hepatology (Baltimore, Md.) 62, no. 2 (August 2015): 409-416.

Full Text

Muir, AJ. "Understanding the Complexities of Cirrhosis." Clinical Therapeutics 37, no. 8 (August 2015): 1822-1836. (Review)

Full Text